David M. Ritter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David M. Ritter has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Darcy A. Krueger
Cincinnati Children's Hospital Medical Center
6 shared publications David N. Franz
Division of Neurology, Cincinnati Children's Hospital Medical Center and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
4 shared publicationsPaul S. Horn
Division of Neurology Cincinnati Children's Hospital Medical Center Cincinnati OH USA; Department of Pediatrics, University of Cincinnati College of Medicine Cincinnati OH USA
4 shared publicationsDarcy A. Krueger
Division of Neurology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center University of Cincinnati College of Medicine Cincinnati OH USA
3 shared publications- David Neal Franz
Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio
3 shared publications - Jamie K. Capal
Cincinnati Children's Hospital Medical Center
3 shared publications
Latest Publications
- Open Access
Amyloid-Independent Elevation of Plasma phosphorylated tau-217 Tracks Neurodegenerative Risk in Tuberous Sclerosis Complex: Implications for mTOR-Targeted Intervention
Background: Tuberous sclerosis complex (TSC) is a rare autosomal dominant neurodevelopmental disorder caused by loss-of-function mutations in TSC1 or TSC2, resulting in chronic hyperactivation of the mechanistic target of rapamycin (mTOR) pathway. TSC patients experience a wide spectrum of cognitive, behavioral, and psychiatric features collectively termed Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND). Moreover, these patients develop a clinical trajectory in adulthood with clinical and neuropathological features overlapping those of Alzheimers disease (AD). Prior neuropathological studies have shown accumulation of AD-type mixed 3R/4R tau isoforms in adults with TSC that is amyloid-independent. Methods: To further explore the biological convergence of TSC and AD, this study compared plasma levels of phosphorylated tau-217 (ptau-217), a sensitive and specific marker of early AD pathology, in 63 TSC, 25 AD, and 116 cognitively unimpaired (CU) patients. Results: Findings revealed elevated levels of plasma ptau-217 in individuals with TSC at younger ages with a parallel age-related trajectory between TSC, AD, and CU cohorts. Multivariable linear regression showed that the log2 ptau-217 concentrations were significantly lower in the CU cohort relative to TSC (β= -0.21, SE = 0.05, p < 0.0001) but were not significantly different between the TSC and AD cohorts (β= 0.17, SE = 0.09, p < 0.071). The comparison of slopes analysis (ANCOVA) supported that the slopes for the regression of log2 ptau-217 versus age are not significantly different for the TSC and CU cohorts (TSC slope = 0.030, SE = 0.008; CU slope = 0.019, SE = 0.006; p = 0.26), nor for the TSC and AD cohorts (TSC slope = 0.030, SE = 0.01; AD slope = 0.06, SE = 0.03; p = 0.099). Conclusions: These results suggest a novel link between TSC and AD that substantiates shared downstream neurodegenerative pathways. Furthermore, these results support the potential utility of ptau-217 as a minimally invasive biomarker for TAND severity, neurodegenerative risk, and AD-like prognosis in TSC and as a tool to guide new mTOR-targeted therapeutic strategies.
Open AccessAmyloid-Independent Elevation of Plasma phosphorylated tau-217 Tracks Neurodegenerative Risk in Tuberous Sclerosis Complex: Implications for mTOR-Targeted Intervention
Background: Tuberous sclerosis complex (TSC) is a rare autosomal dominant neurodevelopmental disorder caused by loss-of-function mutations in TSC1 or TSC2, resulting in chronic hyperactivation of the mechanistic target of rapamycin (mTOR) pathway. TSC patients experience a wide spectrum of cognitive, behavioral, and psychiatric features collectively termed Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders (TAND). Moreover, these patients develop a clinical trajectory in adulthood with clinical and neuropathological features overlapping those of Alzheimers disease (AD). Prior neuropathological studies have shown accumulation of AD-type mixed 3R/4R tau isoforms in adults with TSC that is amyloid-independent. Methods: To further explore the biological convergence of TSC and AD, this study compared plasma levels of phosphorylated tau-217 (ptau-217), a sensitive and specific marker of early AD pathology, in 63 TSC, 25 AD, and 116 cognitively unimpaired (CU) patients. Results: Findings revealed elevated levels of plasma ptau-217 in individuals with TSC at younger ages with a parallel age-related trajectory between TSC, AD, and CU cohorts. Multivariable linear regression showed that the log2 ptau-217 concentrations were significantly lower in the CU cohort relative to TSC (β= -0.21, SE = 0.05, p < 0.0001) but were not significantly different between the TSC and AD cohorts (β= 0.17, SE = 0.09, p < 0.071). The comparison of slopes analysis (ANCOVA) supported that the slopes for the regression of log2 ptau-217 versus age are not significantly different for the TSC and CU cohorts (TSC slope = 0.030, SE = 0.008; CU slope = 0.019, SE = 0.006; p = 0.26), nor for the TSC and AD cohorts (TSC slope = 0.030, SE = 0.01; AD slope = 0.06, SE = 0.03; p = 0.099). Conclusions: These results suggest a novel link between TSC and AD that substantiates shared downstream neurodegenerative pathways. Furthermore, these results support the potential utility of ptau-217 as a minimally invasive biomarker for TAND severity, neurodegenerative risk, and AD-like prognosis in TSC and as a tool to guide new mTOR-targeted therapeutic strategies.
- 7 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 1-9
From Infancy to Early School Age: Longitudinal Developmental Outcomes and Autism Diagnostic Stability in Tuberous Sclerosis Complex
- 7 July 2026
- Published by Elsevier in Pediatric Neurology
- Vol. 183, 1-9
From Infancy to Early School Age: Longitudinal Developmental Outcomes and Autism Diagnostic Stability in Tuberous Sclerosis Complex
- Open Access
- 21 October 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 174, 86-90
Limited Utility for Head Ultrasounds in the Evaluation of Tuberous Sclerosis Complex
- 21 October 2025
- Published by Elsevier in Pediatric Neurology
- Vol. 174, 86-90
Open AccessLimited Utility for Head Ultrasounds in the Evaluation of Tuberous Sclerosis Complex
- Open Access
- 2 July 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (11) , e64175
Maternal Sirolimus Treatment Reverses Cardiac Rhabdomyoma‐Induced Hydrops Fetalis in a Twin Gestation With Tuberous Sclerosis Complex
Cardiac rhabdomyomas are often the presenting sign of tuberous sclerosis complex (TSC). Prior reports have shown that maternal sirolimus treatment can reduce rhabdomyomas. We used maternal sirolimus to reverse hydrops fetalis due to a massive cardiac rhabdomyoma in a twin gestation. This expands the possibilities of prenatal medical treatment in TSC.
- 2 July 2025
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 197 (11) , e64175
Open AccessMaternal Sirolimus Treatment Reverses Cardiac Rhabdomyoma‐Induced Hydrops Fetalis in a Twin Gestation With Tuberous Sclerosis Complex
Cardiac rhabdomyomas are often the presenting sign of tuberous sclerosis complex (TSC). Prior reports have shown that maternal sirolimus treatment can reduce rhabdomyomas. We used maternal sirolimus to reverse hydrops fetalis due to a massive cardiac rhabdomyoma in a twin gestation. This expands the possibilities of prenatal medical treatment in TSC.
- 7 March 2025
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 25 (4) , 389-396
Treating subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: an update of the literature
Subependymal giant cell astrocytomas (SEGAs) are one of the predominant features of the tuberous sclerosis complex (TSC). Before the use of mTOR inhibitors (mTORi; everolimus and sirolimus) in TSC, many patients had to undergo surgical operations (both preemptively and emergently). However, with mTORis gaining increased use, the role of medical and surgical therapy in SEGA is unclear. The authors have based this review on publications listed in PubMed that delve into the role of surgery and mTORi in the treatment of SEGAs. There is no sizable head-to-head comparison of surgery and medical therapy in treating SEGA. Factors that reduce the ability to do these types of studies are the lack of uniform diagnosis of SEGA, provider preference for treatment, and variability in each treatment group (dosing of mTORis and various surgical providers). However, with the safety of mTORi, the authors recommend starting mTORi therapy for any growth in a nodule on serial scans and relying on surgery only for failed mTORi therapy.
- 7 March 2025
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 25 (4) , 389-396
Treating subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: an update of the literature
Subependymal giant cell astrocytomas (SEGAs) are one of the predominant features of the tuberous sclerosis complex (TSC). Before the use of mTOR inhibitors (mTORi; everolimus and sirolimus) in TSC, many patients had to undergo surgical operations (both preemptively and emergently). However, with mTORis gaining increased use, the role of medical and surgical therapy in SEGA is unclear. The authors have based this review on publications listed in PubMed that delve into the role of surgery and mTORi in the treatment of SEGAs. There is no sizable head-to-head comparison of surgery and medical therapy in treating SEGA. Factors that reduce the ability to do these types of studies are the lack of uniform diagnosis of SEGA, provider preference for treatment, and variability in each treatment group (dosing of mTORis and various surgical providers). However, with the safety of mTORi, the authors recommend starting mTORi therapy for any growth in a nodule on serial scans and relying on surgery only for failed mTORi therapy.
- 5 February 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 172, 1-9
Altered cortical excitability in tuberous sclerosis and the effect of mTOR inhibitors: An intracranial electrical stimulation study
- 5 February 2025
- Published by Elsevier in Clinical Neurophysiology
- Vol. 172, 1-9
Altered cortical excitability in tuberous sclerosis and the effect of mTOR inhibitors: An intracranial electrical stimulation study
- 27 September 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 161, 201-207
Cenobamate's Efficacy for Seizure Treatment in Tuberous Sclerosis Complex
- 27 September 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 161, 201-207
Cenobamate's Efficacy for Seizure Treatment in Tuberous Sclerosis Complex
- 7 September 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 161, 73-75
Mammalian Target of Rapamycin Inhibitor Levels Decrease Under Cenobamate Treatment
- 7 September 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 161, 73-75
Mammalian Target of Rapamycin Inhibitor Levels Decrease Under Cenobamate Treatment
- 1 June 2024
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 39 (7-8) , 268-274
Impact of Race in Missed Appointments in Pediatric Neurology Resident Clinic at a Large Tertiary Medical Center
Missed medical appointments are a common problem across specialties. The discontinuity of care leads to unplanned health care utilization, increased costs, and poor health outcomes. Previous studies evaluating pediatric epilepsy have shown significant socioeconomic barriers to care. In several specialties, resident clinic no-show rates are higher than faculty clinics because of socioeconomic barriers. We sought to understand the relationship between race, socioeconomic factors, and missed appointments in a pediatric neurology resident clinic at a large tertiary care hospital. Resident clinic encounters for 1 year were extracted and analyzed for missed appointments, socioeconomic factors, and health care utilization. We found that missed appointments occur for 1 in 5 patients and correlate with socioeconomic factors (eg, income and insurance) and race. Race was a more significant factor than socioeconomic factors for missed appointments. These results provide areas to target and track interventions to improve health outcomes in children in pediatric neurology clinics.
- 1 June 2024
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 39 (7-8) , 268-274
Impact of Race in Missed Appointments in Pediatric Neurology Resident Clinic at a Large Tertiary Medical Center
Missed medical appointments are a common problem across specialties. The discontinuity of care leads to unplanned health care utilization, increased costs, and poor health outcomes. Previous studies evaluating pediatric epilepsy have shown significant socioeconomic barriers to care. In several specialties, resident clinic no-show rates are higher than faculty clinics because of socioeconomic barriers. We sought to understand the relationship between race, socioeconomic factors, and missed appointments in a pediatric neurology resident clinic at a large tertiary care hospital. Resident clinic encounters for 1 year were extracted and analyzed for missed appointments, socioeconomic factors, and health care utilization. We found that missed appointments occur for 1 in 5 patients and correlate with socioeconomic factors (eg, income and insurance) and race. Race was a more significant factor than socioeconomic factors for missed appointments. These results provide areas to target and track interventions to improve health outcomes in children in pediatric neurology clinics.